Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC)

被引：0
|
作者：
Gulley, James L. [1 ]
Arlen, Philip M. [1 ]
Madan, Ravi [1 ]
Lechleider, Robert L. [1 ]
Dahut, William L. [1 ]
Lowy, Israel [2 ]
Schlom, Jeffrey [1 ]
机构：
[1] NCI, Bethesda, MD USA
[2] Medarex, Princeton, NJ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3381S / 3381S
页数：1
相关论文
共 50 条
  • [21] A JOINT MODEL RELATING CHANGES IN PROSTATE SPECIFIC ANTIGEN (PSA) TO SURVIVAL IN CASTRATE RESISTANT PROSTATE CANCER (CRPC).
    Mai, T. H.
    Gray, E.
    Sharma, M. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S12 - S12
  • [22] Phase II trial of cediranib (AZD 2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P.
    Mulquin, M.
    Wright, J.
    Turkbey, I. B.
    Choyke, P.
    Ahlers, C. M.
    Figg, W. D.
    Dahut, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [23] A JOINT MODEL RELATING CHANGES IN PROSTATE SPECIFIC ANTIGEN (PSA) TO SURVIVAL IN CASTRATE RESISTANT PROSTATE CANCER (CRPC).
    Mai, T. H.
    Gray, E.
    Sharma, M. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S105 - S105
  • [24] Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).
    Morris, Michael J.
    Bruce, Justine Yang
    Reyno, Leonard M.
    Anand, Banmeet
    Hartford, Alan
    Jelaca-Maxwell, Kathy
    Lackey, Jacqueline
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Combination of a polyamine-free oral nutritional supplement (ONS) with docetaxel in castrate-resistant prostate cancer (CRPC) patients (pts): A phase II trial.
    Cipolla, Bernard G.
    Artignan, Xavier
    Miglianico, Laurent
    Bligny, Dominique
    Abraham, Christine
    Moulinoux, Jacques Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219): Evaluation of bone metastasis microenvironment
    Grivas, Petros
    Daignault, Stephanie
    Cooney, Kathleen A.
    Jacobson, Jon
    Yablon, Corrie
    Ross, Brian Dale
    Chenevert, Thomas L.
    Hoff, Ben
    Rehemtulla, Alnawaz
    Keller, Evan T.
    Mehra, Rohit
    Shelley, Greg
    Alva, Aijai Shivaram
    Hussain, Maha
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer
    Vaishampayan, Ulka N.
    Marur, Shanthi
    Heilbrun, Lance K.
    Cher, Michael L.
    Dickow, Brenda
    Smith, Daryn W.
    Al Hasan, Samir A.
    Eliason, James
    JOURNAL OF UROLOGY, 2009, 182 (01): : 317 - 323
  • [28] Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC).
    Milowsky, M. I.
    Galsky, M.
    George, D. J.
    Lewin, J. M.
    Rozario, C. P.
    Marshall, T.
    Chang, M.
    Nanus, D. M.
    Webb, I. J.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 217S - 217S
  • [29] Time to biochemical and radiographic progression in patients treated with adenovirus-PSA vaccine for non-metastatic/early metastatic castrate-resistant prostate cancer: Phase 2 trial results.
    Vaena, Daniel A.
    Nepple, Kenneth Gerard
    Brown, James A.
    Griffith, Karen
    Zehr, Pamela
    Lubaroff, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Caroline Jochems
    Jo A. Tucker
    Kwong-Yok Tsang
    Ravi A. Madan
    William L. Dahut
    David J. Liewehr
    Seth M. Steinberg
    James L. Gulley
    Jeffrey Schlom
    Cancer Immunology, Immunotherapy, 2014, 63 : 407 - 418
12345